{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-280241","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.653526+00:00","generated_at":"2026-06-22T03:54:12.042497+00:00","sec_items":["2.01","1.01","5.07","3.02","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Silverback Therapeutics merges with ARS Pharma; renamed ARS Pharmaceuticals, new board and focus on neffy","bullets":["Merger completed Nov 8, 2022; ARS Pharma becomes wholly owned subsidiary of re-named ARS Pharmaceuticals, Inc.","ARS Pharma equityholders own ~62% and prior Silverback equityholders ~38% on a fully diluted basis post-merger.","New board includes eight ARS Pharma designees; executives: Richard Lowenthal (CEO), Kathleen Scott (CFO), Sarina Tanimoto (CMO), Eric Karas (CCO), Justin Chakma (CBO/Secretary).","Company now focusing on neffy (intranasal epinephrine) for Type I allergic reactions and anaphylaxis.","Stock symbol changes from SBTX to SPRY, effective Nov 9, 2022, on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-280241","json":"https://secwatch.observer/filing/0001193125-22-280241.json","markdown":"https://secwatch.observer/filing/0001193125-22-280241.md","text":"https://secwatch.observer/filing/0001193125-22-280241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/d388226d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:54:12.042497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12decb52bd","claim":"Maria Koehler resigned as Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"23e1b612e0","claim":"Andrew Powell resigned as Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"337432e10a","claim":"Vicki L. Capps resigned as Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"39f3836f41","claim":"Rajeev Dadoo was appointed as Class I Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Rajeev Dadoo, Ph.D. 52 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"4efec2959a","claim":"Sarina Tanimoto was appointed as Chief Medical Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Sarina Tanimoto, M.D., M.B.A. 54 Chief Medical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"5ae5332c69","claim":"Brenton L. Saunders was appointed as Class II Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Brenton L. Saunders 52 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"6cd7839b95","claim":"Peter Kolchinsky was appointed as Class II Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Peter Kolchinsky, Ph.D. 46 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"72556d8065","claim":"Pratik Shah was appointed as Chair of the Board and Class I Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Pratik Shah, Ph.D. 52 Chair of the Board and Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board and Class I Director"}],"fact_type":"executive_change"},{"claim_id":"7a8dbdc72a","claim":"Russ Hawkinson was terminated as Interim Chief Financial Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"each of Jeffrey Pepe, Ph.D., J.D., the Company’s Interim Chief Executive Officer, General Counsel and Corporate Secretary, and Russ Hawkinson, the Company’s Interim Chief Financial Officer, were terminated in connection with the Company’s previously announced reduction in force.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"873cfcccba","claim":"Justin Chakma was appointed as Chief Business Officer and Secretary at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Justin Chakma 33 Chief Business Officer and Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Business Officer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"9b303401c8","claim":"Robert Hershberg resigned as Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a7c3fcd120","claim":"Eric Karas was appointed as Chief Commercial Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Eric Karas 50 Chief Commercial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"b235d0ca46","claim":"Phillip Schneider was appointed as Class III Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Phillip Schneider 66 Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"bbb753f8a9","claim":"Jeffrey Pepe was terminated as Interim Chief Executive Officer, General Counsel and Corporate Secretary at ARS Pharmaceuticals, Inc..","evidence_excerpt":"each of Jeffrey Pepe, Ph.D., J.D., the Company’s Interim Chief Executive Officer, General Counsel and Corporate Secretary, and Russ Hawkinson, the Company’s Interim Chief Financial Officer, were terminated in connection with the Company’s previously announced reduction in force.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Interim Chief Executive Officer, General Counsel and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"ca84348658","claim":"Jonathan S. Leff was appointed as Class III Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Jonathan S. Leff 53 Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"e108ada0aa","claim":"Richard Lowenthal was appointed as President and Chief Executive Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Richard Lowenthal, M.S., MSEL 56 President, Chief Executive Officer and Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e15022877b","claim":"Kathleen Scott was appointed as Chief Financial Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Kathleen Scott 53 Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"fa143d388b","claim":"Jonathan Root resigned as Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fcb8990c13","claim":"Michael Kelly was appointed as Class I Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Michael Kelly 57 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"fd4dd667d8","claim":"Richard Lowenthal was appointed as Class II Director at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Pursuant to the terms of the Merger Agreement, each of (i) Mr. Lowenthal, Dr. Shah, Dr. Dadoo, Mr. Kelly, Dr. Kolchinsky, Mr. Leff, Mr. Saunders and Mr. Schneider were appointed to the board of directors of the Company as designees of ARS Pharma","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"87b2a012a45fc41260939d009ed8a3611e428d1d","claim":"ARS Pharmaceuticals, Inc.: Silverback Therapeutics, Inc. changed its name to ARS Pharmaceuticals, Inc. via a charter amendment effective upon merger consummation (effective 2022-11-08).","evidence_excerpt":"on November 8, 2022, Silverback filed the Charter Amendment changing its name from \"Silverback Therapeutics, Inc.\" to \"ARS Pharmaceuticals, Inc.\"","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-11-08"}],"fact_type":"governance_change"},{"claim_id":"786aae0cede9f16a7479c81ba0610ae4adc21334","claim":"ARS Pharmaceuticals, Inc. underwent a change of control involving ARS Pharmaceuticals, Inc. (closed 2022-11-08).","evidence_excerpt":"On November 8, 2022, Silverback, Merger Sub and ARS Pharma consummated the transactions contemplated by the Merger Agreement","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"ARS Pharmaceuticals, Inc."},{"label":"Closing","value":"2022-11-08"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}